
CRISPR Therapeutics (CRSP) Stock Forecast & Price Target
CRISPR Therapeutics (CRSP) Analyst Ratings
Bulls say
CRISPR Therapeutics is supported by accelerating Casgevy momentum, with 3Q:26 sales of $99.2M topping Street estimates and infusions through 3Q:26 doubling FY:25 levels, reinforcing confidence that reimbursement, penetration, and the pediatric label expansion can drive continued growth. Beyond the commercial launch, CTX310 has shown durable one-year reductions in ANGPTL3, LDL-C, and triglycerides with favorable safety, strengthening the case for a potentially differentiated one-time cardiovascular therapy. The balance sheet and pipeline also support the outlook, with about $2.2B in estimated YE:26 cash and multiple clinical assets advancing in immuno-oncology, cardiovascular disease, and Type 1 diabetes.
Bears say
CRISPR Therapeutics is viewed negatively because the bull case depends heavily on Casgevy, yet sales may fail to accelerate and several earlier-stage programs could be discontinued, which would pressure valuation and reduce future growth optionality. The company also faces substantial development risk across exa-cel, CTX112, CTX310, CTX340, CTX460, and CTX611, including uncertainty around safety, efficacy, and durability in clinical trials, all of which is amplified by the novelty of gene editing. On top of that, commercialization is challenged by competing programs in beta thalassemia, sickle cell disease, and CD19 oncology, while unresolved intellectual property issues and manufacturing, legal, regulatory, and financial risks further weaken the investment case.
This aggregate rating is based on analysts' research of CRISPR Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
CRISPR Therapeutics (CRSP) Analyst Forecast & Price Prediction
Start investing in CRISPR Therapeutics (CRSP)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About CRISPR Therapeutics (CRSP) Forecast
CRISPR Therapeutics (CRSP) Analyst Forecast & Price Prediction
Start investing in CRISPR Therapeutics (CRSP)
Order type
Buy in
Order amount
Est. shares
0 shares